Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus
Authors:
- PRECISESADS Clinical ConsortiumPCPRECISESADS Clinical Consortium
- Ioannis ParodisIoannis Parodis
Open Access
- 30 November 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1257085
Abstract
Introduction: Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease that presents a challenge for clinicians. To identify potential biomarkers for diagnosis and disease activity in SLE, we investigated a selected yet broad panel of cytokines and autoantibodies in patients with SLE, healthy controls (HC), and patients with other autoimmune diseases (AIDs).Methods: Serum samples from 422 SLE patients, 546 HC, and 1223 other AIDs were analysed within the frame of the European PRECISESADS project (NTC02890121). Cytokine levels were determined using Luminex panels, and autoantibodies using different immunoassays.Results: Of the 83 cytokines analysed, 29 differed significantly between patients with SLE and HC. Specifically, CCL8, CXCL13, and IL-1RA levels were elevated in patients with active, but not inactive, SLE versus HC, as well as in patients with SLE versus other AIDs. The levels of these cytokines also correlated with SLE Disease Activity Index 2000 (SLEDAI-2K) scores, among five other cytokines. Overall, the occurrence of autoantibodies was similar across SLEDAI-2K organ domains, and the correlations between autoantibodies and activity in different organ domains were weak.Discussion: Our findings suggest that, upon validation, CCL8, CXCL13, and IL-1RA could serve as promising serum biomarkers of activity in SLE.Keywords
Funding Information
- Reumatikerförbundet (R-969696)
- Stiftelsen Konung Gustaf V:s 80-årsfond (FAI-2020-0741)
- Svenska Läkaresällskapet (SLS-974449)
- Nyckelfonden (OLL-974804)
- Stiftelsen Professor Nanna Svartz Fond (2021-00436)
- Karolinska Institutet
- Innovative Medicines Initiative (115565, 831434)
This publication has 48 references indexed in Scilit:
- IFNα Inducible Models of Murine SLEFrontiers in Immunology, 2013
- The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritisJournal of Clinical Investigation, 2010
- Anakinra for rheumatoid arthritisCochrane Database of Systematic Reviews, 2009
- Elevated Serum Levels of Interferon-Regulated Chemokines Are Biomarkers for Active Human Systemic Lupus ErythematosusPLOS Medicine, 2006
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritisAnnals of the Rheumatic Diseases, 2005
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in BiologyAnnual Review of Immunology, 1998
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992